目的 评价CD24蛋白表达在术后放疗宫颈癌患者中的预后意义。方法 免疫组织化学法检测140例术后放疗的宫颈癌患者癌组织中CD24蛋白的表达情况。结果 59例（42%）宫颈癌患者中CD24蛋白表达阳性，单因素分析表明，CD24阳性表达与局部区域无失败生存率（P =0.022）、无远处转移生存率（P =0.000）和总生存率（P =0.005）呈显著相关性。多元回归分析发现CD24阳性表达与无远处转移生存率（P =0.025）和总生存率（P =0.045）呈显著相关性。单独RT组CD24表达与LRFFS（P =0.020）呈显著相关性，CRT组CD24表达与DMFS（P =0.000）呈显著相关性。结论 CD24表达是术后放疗宫颈癌患者的独立预后标志物，且在术后辅助CRT和单独RT治疗中预后意义不同。制定宫颈癌患者个性化治疗方案需参考患者CD24表达情况。
Objective To evaluate the prognostic significance of CD24 protein overexpression in patients treated with post-operative radiotherapy (RT) after surgery. Methods We determined the CD24 expression status of 140 patients with cervical carcinoma treated with RT alone or with chemoradiotherapy (CRT) after radical hysterectomy procedures. Results CD24 expression was detected in 59 patients (42 %) and was significantly associated with locoregional failure-free survival (LRFFS) (P = 0.022), distant metastasis-free survival (DMFS) (P = 0.000), and overall survival (OS) (P = 0.005). In the multivariate analysis, CD24 positivity was also significantly associated with DMFS (P = 0.025) and OS (P = 0.045). CD24 expression was associated with DMFS (P = 0.000) in the CRT group. However, CD24 expression was associated with LRFFS (P = 0.020) in the RT alone group. Conclusions CD24 expression is an independent prognostic marker in patients with cervical squamous cell carcinoma, even with post-hysterectomy adjuvant treatment. This study revealed a different prognostic role for CD24 expression in adjuvant CRT and RT alone treatment groups after surgery. New therapeutic strategies targeting CD24 expression stratified by subgroups might have important clinical implications.